MIRM240719P17500
- 0.08
- 0.000.00%
Mirum Pharmaceuticals Newsroom
The 9.9% Return This Week Takes Mirum Pharmaceuticals' (NASDAQ:MIRM) Shareholders Five-year Gains to 183%
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. For example, the Mirum Pharmaceuticals,
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $69.According to TipRanks data, the analyst has a success
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Mirum Pharmaceuticals (NASDAQ:MIRM) Delivers Shareholders Solid 23% CAGR Over 5 Years, Surging 11% in the Last Week Alone
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Express News | Janus Henderson Group Discloses 10.6% Passive Stake In Mirum Pharmaceuticals As Of June 28
Express News | Janus Henderson Group PLC Discloses 10.6% Passive Stake in Mirum Pharmaceuticals as of June 28 - SEC Filing
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $69
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and adjusts the target price from $68 to $69.According to TipRanks data, the analyst has a
Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections
Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe
Mirum Pharmaceuticals (MIRM) said Monday that the European Commission has approved the marketing of its oral treatment Livmarli for progressive familial intrahepatic cholestasis, or PFIC, in patients
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
Shares of Mirum Pharmaceuticals, Inc. (MIRM Quick QuoteMIRM - Free Report) have rallied 31.5% in the past three months against the industry’s decrease of 1.5%.
Mirum Pharmaceuticals' LIVMARLI Approved In The EU For Patients With PFIC In Patients 3-Months Of Age And Older
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older.Approval follows positive opinion from CHMP concluding LIVMARLI's clinical benefit
Express News | Mirum Pharmaceuticals : European Commission Grants Livmarli Marketing Authorization for Treatment of Pfic in Patients Three Months & Older
Express News | Mirum Pharmaceuticals : Livmarli Also Received Positive Comp Opinion Recommending Maintenance of Orphan Drug Designation in Pfic
Express News | Mirum Pharmaceuticals’ Livmarli Approved in the European Union for Patients With Pfic
Form 144 | Mirum Pharmaceuticals(MIRM.US) Officer Proposes to Sell 1.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Mirum Pharmaceuticals(MIRM.US)$ Officer LARA LONGPRE intends to sell 30,559 shares of its common stock on Jul 1, with a total market value of approximately $1.07 millio
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $68
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $68.According to TipRanks data, the analyst has a success rate
Mirum Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 104.21% HC Wainwright & Co. $66 → $66 Reiterates Buy → Buy 06/20/2024 104.21% Stifel $48 → $66